Draxis, Merck Frosst Canada Inc. deal

DRAXF completed its $13.5 million acquisition of Merck Frosst’s radiopharmaceutical division, which

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE